OmniAb, Inc. (NASDAQ:OABIW – Get Free Report) was the recipient of a significant drop in short interest in May. As of May 29th, there was short interest totaling 9,581 shares, a drop of 33.6% from the May 14th total of 14,433 shares. Based on an average daily volume of 8,727 shares, the days-to-cover ratio is presently 1.1 days.
OmniAb Stock Performance
OABIW stock opened at $0.09 on Thursday. The business has a 50 day moving average price of $0.10 and a two-hundred day moving average price of $0.10. OmniAb has a twelve month low of $0.05 and a twelve month high of $0.30.
About OmniAb
OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.
Featured Articles
- Five stocks we like better than OmniAb
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
